⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 24, 2024

[Preliminary study on the role and mechanism of IL-6 receptor antagonists in improving post-infarction ventricular arrhythmia].

Qinfang Qiu Cheng Peng Z Y Li Xiangyang Xu Hualin Simon Xi T Y Liu Wilson Tan Jia Huang Lingbo Zhou Yang Wang Hong Jiang

View at Publisher

Ask AI

Bookmark

Share

Abstract

To investigate the effect of tocilizumab (TCZ) on ventricular arrhythmias (VAs) after myocardial infarction (MI) in Sprague-Dawley rats and explore its potential mechanism.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Qiu et al. (2024) studied this question.

synapsesocial.com/papers/68e5f3f5b6db6435875887be https://doi.org/10.3760/cma.j.cn112148-20240316-00148

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Tocilizumab in the treatment of myocardial infarctionreview · 2018 · 13 citations
2Interleukin-6 Inhibition for Patients with Acute Myocardial Infarction: <i>A Systematic Review and Meta-Analysis</i>meta-analysis · 2026
3Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trialRCT · 2016 · 401 citations
4Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumabRCT · 2023 · 10 citations
5Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trialother · 2024 · 13 citations

More related papers

Tocilizumab does not ameliorate inflammation-induced left ventricular dysfunction in a collagen-induced arthritis rat model2024
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)2019
Effect of Interleukin-6 Receptor Inhibition by Tocilizumab on Platelet Activation and Markers of Thrombus Formation: A Substudy of the ASSAIL-MI Trial2026